PLEASANTON, CA--(Marketwire - February 19, 2008) - Lipid Sciences, Inc. (NASDAQ: LIPD) announced today that Elanco, a division of Eli Lilly and Company (NYSE: LLY), has exercised its right to “opt in” with a development plan and additional investment on a vaccine study.
